ArticlePloS one2026
Neutrophil extracellular traps in the animal model of adenine-induced chronic kidney disease.
Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Neutrophil extracellular traps (NETs) are suggested to play a role in chronic kidney disease (CKD). Whether they are indeed involved in the pathogenesis of animal models of CKD has not been proved. This study tested the hypothesis that a genetic deficiency of peptidylarginine deiminase 4 (PAD4) - a regulator of NETs production will protect mice from developing adenine-induced nephropathy as a model of CKD. Adult male Padi4-/- mice and their wild-type counterparts received 100 mg/kg adenine or saline i.p. daily for 14 days. Markers of renal function and NETs-related biomarkers were assessed during the CKD induction in plasma and urine. In wild-type mice, adenine injections decreased body weight by 20% and increased plasma creatinine (twofold), neutrophil gelatinase-associated lipocalin (21-fold), and neutrophil elastase (4-fold). No significant differences were found between the Padi4-/- and wild-type mice except the earlier increase in plasma creatinine in Padi4-/- mice (day 3 vs. day 7). Analyses of neutrophil elastase and myeloperoxidase in plasma and urine suggest that neutrophils are activated in adenine-induced nephropathy, but the production of NETs seems not to be directly involved in the pathogenesis of this CKD model. Further studies should clear the role of NETs in other kidney disease models with clinical relevance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.